James Garner

James Garner

Company: Kazia Therapeutics

Job title: Chief Executive Officer & Managing Director


Beyond Hematological Malignancies: the Case for PI3K Inhibition in Brain Cancer 11:15 am

• Relevance of the PI3K pathway to primary and secondary brain cancers • Opportunities and challenges in the application of PI3K inhibitors to brain cancer Paxalisib – a novel PI3K / mTOR inhibitor in development for glioblastomaRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.